This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher (TMO) Q3 Earnings Beat on Life Sciences Sales
by Zacks Equity Research
Significant COVID-19 led business expansions, as well as Thermo Fisher's (TMO) base business growth contribute to a stunning Q3 performance.
The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed
3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings
by Zacks Equity Research
Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.
Intuitive Surgical (ISRG) Q3 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect improvement in procedure volume.
Zacks.com featured highlights include: Lowe's, ResMed, Artisan Partners and Northern Trust
by Zacks Equity Research
Zacks.com featured highlights include: Lowe's, ResMed, Artisan Partners and Northern Trust
Is ResMed (RMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (RMD) Outperforming Other Medical Stocks This Year?
Walgreens Boots (WBA) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) fiscal fourth-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.
4 MedTech Stocks to Enrich Your Portfolio Ahead of Q3 Earnings
by Trina Mukherjee
Grab these four stocks that continue to show tremendous promise despite market volatility resulting from the coronavirus pandemic.
4 GARP Stocks to Scoop Up for Maximum Returns
by Shilpa Mete
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
Add These 5 Stocks With Impressive Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
3 Growth-Focused MedTech Stocks to Buy Amid the COVID-19 Crisis
by Debanjana Dey
Here are three growth stocks from the MedTech space which have maintained stellar performance even during the pandemic-led market meltdown.
Veeva's Vault eTMF Gets Implemented by Biotest for Trials
by Zacks Equity Research
Veeva's (VEEV) Vault eTMF should enable Biotest to manage all study documents and activities in real time.
3 Stocks to Buy From Strong MedTech Spaces Amid the Pandemic
by Debanjana Dey
Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be positive about ResMed (RMD) owing to its robust product line and consistent high demand for its critical care products.
Veeva Vault Picked by AstraZeneca for Quality Management
by Zacks Equity Research
The partnership with AstraZeneca will facilitate end-to-end quality management for Veeva (VEEVA).
Buy 4 Beaten-Down MedTech Value Stocks Amid September Selloffs
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.
4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus
by Debanjana Dey
Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.
Why Is ResMed (RMD) Up 1.3% Since Last Earnings Report?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
ResMed (RMD) Launches First CPAP Nasal Mask With Memory Foam
by Zacks Equity Research
ResMed (RMD) adds another product to its line of easy-to-use, convenient and comfortable masks.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be upbeat about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
ResMed (RMD) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
ResMed's (RMD) top line reflects strong segmental and geographic performance boosted by pandemic-led demand growth for ventilators.